

2 June 2026

Companies Announcements Office  
Australian Securities Exchange

## ImpediMed Share Purchase Plan

**Reminder: Applications close at 5.00pm (Sydney time) on Friday, 5 June 2026**

**ImpediMed Limited** (ASX:IPD) (**ImpediMed** or the **Company**) advises the SPP announced on Monday, 4 May will close at 5.00pm (Sydney time) on Friday, 5 June 2026.

- The SPP follows ImpediMed's A\$13.2 million institutional placement to sophisticated and institutional investors at an issue price of A\$0.010 per share (**Placement**).
- Eligible shareholders in Australia and New Zealand have the opportunity to apply for up to A\$100,000 of SPP Shares without incurring brokerage, commissions, or other transaction costs.
- Participants in the SPP will receive one free attaching option per SPP Share subscribed for, and a further option that may be exercised following the valid exercise of the first attaching option.
- Completion of the SPP and the issue of each of the options is subject to obtaining shareholder approval at a general meeting of shareholders scheduled to occur in mid-June 2026 (**EGM**).

The SPP aims to raise up to A\$2.0 million via the issue of up to 200 million new shares. ImpediMed reserves the right to increase the size of the SPP and accept oversubscriptions of up to an additional 100 million new shares, at its discretion. The SPP may also be subject to a scale back of applications, which will be done on a pro rata basis.

The issue price of the SPP Shares will be the lower of:

- A\$0.010 per new share (i.e. the offer price under the Placement); or
- a 2.5% discount to the VWAP of the Company's ordinary shares traded on the ASX during the 5 trading days up to the closing date of the SPP, rounded to the nearest 0.1 cent.

Consistent with the Placement, each participant in the SPP will receive:

- one free attaching option (exercisable at \$0.010 each and expiring on 31 March 2027) (**Attaching Option**) for every share subscribed for in the SPP; and

# impedimed®

- a further option (exercisable at \$0.015 per option and expiring on 31 December 2027) (**Follow-on Option**, and together with the Attaching Options, the **Options**) that may be exercised following the valid exercise of an Attaching Option by that holder, in each case, subject to shareholders approving the issue of the Options at the EGM.

All Options are intended to be quoted, subject to satisfying ASX requirements for listing.

To apply for SPP Shares, Eligible Shareholders must by 5.00pm (AEST) on the Closing Date, either:

- download the Prospectus and the personalised application form at <https://events.miraqle.com/ipd-spp/> and make a payment directly via BPAY® (all Eligible Shareholders); or
- download the Prospectus and the personalised application form at <https://events.miraqle.com/ipd-spp/> return the application form and make a payment directly via Electronic Funds Transfer (EFT) (New Zealand Eligible Shareholders only).

The SPP is subject to the terms and conditions set out in the Prospectus, sent to Eligible Shareholders on 12 May 2026. Eligible Shareholders are encouraged to read the Prospectus carefully and, if they are in any doubt about whether to participate in the SPP, to consult their stockbroker, accountant, financial adviser, solicitor or other professional adviser.

## Key dates for capital raising

Event	Date
Record date for determining eligibility to participate in the SPP	7:00PM (AEST) on Friday, 1 May 2026
Announcement of the Capital Raise and lodgement of the Prospectus	Monday, 4 May 2026
Tranche 1 of Placement shares are issued and commence trading	Friday, 8 May 2026
SPP offer period opens	Tuesday, 12 May 2026
SPP offer period closes	5:00PM (AEST) on Friday, 5 June 2026
Announcement of the SPP results	Wednesday, 10 June 2026
EGM held	11:00AM (AEST) on Thursday, 11 June 2026
Issue of shares under Tranche 2 of the Placement and the SPP and the new shares commence trading Issue of Options under the Placement and SPP	Before 12:00PM (AEST) on Monday, 15 June 2026

## Further Information

If you are an Eligible Shareholder and would like further information, please call ImpediMed's Registry, between 8.30am and 5.00pm (AEST) Monday to Friday on +61 1300 853 481 before the SPP closes.

For more information, contact Investor Relations at [investorrelations@impedimed.com](mailto:investorrelations@impedimed.com).

**Approved for release by the Board of ImpediMed Limited**



### **About ImpediMed**

Headquartered in Sydney, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2024, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Survivorship continue to reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit [www.impedimed.com](http://www.impedimed.com).

### **Forward looking statements**

This announcement contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

While management has prepared this information based on its current knowledge and understanding and in good faith, there are risks and uncertainties involved which could cause actual results to differ from projections. You should not place undue reliance on forward-looking statements which speak only as of the date when made. Except as required by law, ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements and no representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including ImpediMed Limited).